A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Huntington's Disease

In brief

This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.

Key facts

Study ID

NCT00497159

Run by

Medivation, Inc.

People needed

91

Starts

2007-07-01

Expected to finish

2008-06-01

Last updated by the study team

2015-06-08

Who can join

Age: 29 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical features of HD and a confirmatory family history of HD, and/or genetically confirmed HD;
• Able to take medication (capsules) by mouth.

You may not qualify if…

• Clinical evidence of unstable medical illness;
• Females who are pregnant or lactating or who intend to become pregnant during the study period.

Where it is running

• Huntington Study Group — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.